Capsaicin (Qutenza)

Small molecule

Also known as NGX-4010

Approvedregulatory verdict

Evidence outlook

Approved: Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN)
Product first approved 2009FDA label
EU
  • Treatment of peripheral neuropathic pain in adults, alone or in combination with other medicinal products for pain (diabetic polyneuropathy added by later label extension)
Product first approved 2009EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Diabetic Peripheral Neuropathic Pain
Other / comorbidity
NCT05997979 · University Hospital, Brest
2024-03-05 – 2028-07-05 · Neuropathic Pain, Chronic Pain
What this study did
NCT05840562 · Institut Cancerologie de l'Ouest
2023-10-20 – 2028-03 · Chemotherapy-induced Peripheral Neuropathy
What this study did
NCT06023706 · Nantes University Hospital
2023-11-08 – 2027-10-08 · Coccyx Disorder, Neuropathic Pain, Coccygodynia
What this study did
NCT04967664 · Averitas Pharma, Inc.
2021-07-13 – 2025-08-28 · Post Surgical Neuropathic Pain
What this study did
NCT03794388 · Institut Cancerologie de l'Ouest
2019-03-19 – 2022-11-18 · Breast Cancer Patient
What this study did
NCT02822625 · Institut de Cancérologie de Lorraine
2016-08-30 – 2019-07-13 · Pain
What this study did
NCT03153813 · Nadine ATTAL
2015-07 – 2018-12 · Pain
What this study did
NCT01699854 · Copenhagen University Hospital, Rigshospitalet
2012-08 – 2013-09 · Persistent Pain After Inguinal Herniotomy
What this study did
NCT00068081 · NeurogesX
Run by former owner NeurogesX, Inc.
— · Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
What this study did
NCT00085761 · NeurogesX
Run by former owner NeurogesX, Inc.
— · HIV Infections, Peripheral Nervous System Diseases, Pain
What this study did
NCT00321672 · NeurogesX
Run by former owner NeurogesX, Inc.
2006-06 – 2007-12 · Pain, HIV Infections, Peripheral Nervous System Diseases
What this study did
NCT00300222 · NeurogesX
Run by former owner NeurogesX, Inc.
2006-03 – 2007-08 · Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster, Shingles
What this study did
NCT00115310 · NeurogesX
Run by former owner NeurogesX, Inc.
2005-06 – 2006-10 · Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster, Shingles
What this study did
NCT00064623 · NeurogesX
Run by former owner NeurogesX, Inc.
2003-08 – 2005-11 · HIV Infections, Peripheral Nervous System Diseases, Pain
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT02854670 · Centre Hospitalier Universitaire de Besancon
2016-01-20 – 2021-02-03 · Vestibulodynia
What this study did
NCT00061776 · NeurogesX
Run by former owner NeurogesX, Inc.
— · Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
What this study did
Phase 2 (11)
Diabetic Peripheral Neuropathic Pain
NCT00082316 · NeurogesX
Run by former owner NeurogesX, Inc.
— · Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies
What this study did
NCT00089557 · NeurogesX
Run by former owner NeurogesX, Inc.
— · Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies
What this study did
Other / comorbidity
NCT04704453 · Institut Claudius Regaud
2021-04-28 – 2025-04-28 · Head and Neck Cancer
What this study did
NCT05543837 · Instituto Mexicano del Seguro Social
2022-09-20 – 2023-02-28 · Cerebral Circulatory Disorder
What this study did
NCT03317613 · Centre Hospitalier Universitaire de Saint Etienne
2017-11-09 – 2021-12-20 · Neuropathic Pain
What this study did
NCT01393795 · Imperial College London
2011-08 – 2012-07 · Pulmonary Hypertension, Pain
What this study did
NCT01260454 · University of Rochester
2010-11 – 2012-04 · Pulmonary Hypertension, Pulmonary Arterial Hypertension
What this study did
NCT00916942 · NeurogesX
Run by former owner NeurogesX, Inc.
2009-06 – 2009-07 · Postherpetic Neuralgia
What this study did
NCT00061152 · NeurogesX
Run by former owner NeurogesX, Inc.
— · HIV Infections
What this study did
NCT00233155 · NeurogesX
Run by former owner NeurogesX, Inc.
2005-08 – 2006-12 · Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases
What this study did
NCT00034710 · NeurogesX
Run by former owner NeurogesX, Inc.
2002-03 – 2002-10 · Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT02769910 · Hjalte Holm Andersen
2016-05 – 2016-07 · Pruritus
What this study did
NCT02228928 · Samyang Biopharmaceuticals Corporation
2009-02 – 2011-05 · Peripheral Nerve Injury, Postherpetic Neuralgia
What this study did
Phase 1 (6)
Other / comorbidity
NCT06744816 · M.D. Anderson Cancer Center
2025-12-11 – 2027-11-30 · Peripheral Neuropathy Due to Chemotherapy
What this study did
NCT04545892 · Juan Manuel Marquez Romero
2019-12-01 – 2020-07-31 · Stroke
What this study did
NCT03899246 · Children's Hospital of Michigan
2019-07-03 – 2020-03-30 · Neuropathic Pain, Sickle Cell Disease
What this study did
NCT00912262 · NeurogesX
Run by former owner NeurogesX, Inc.
2008-06 – 2008-11 · Pain
What this study did
NCT00528216 · NeurogesX
Run by former owner NeurogesX, Inc.
— · Pain
What this study did
NCT00254449 · NeurogesX
Run by former owner NeurogesX, Inc.
2005-11 – 2006-05 · Human Volunteers
What this study did
Phase 4 (8)
Diabetic Peripheral Neuropathic Pain
NCT04238208 · Corporacion Parc Tauli
2019-01-10 – 2020-01-02 · Diabetic Nerve Problems, Diabetic Neuropathy, Diabetic Complications Neurological
What this study did
Other / comorbidity
NCT06444919 · University Hospital, Clermont-Ferrand
2025-03-07 – 2028-01-01 · Osteoarthritis Hand, Neuropathic Pain
What this study did
NCT03348735 · University Hospital, Antwerp
2018-12-03 – 2021-04-19 · Neuropathic Pain
What this study did
NCT02570841 · Medical University of Vienna
2015-02 – 2015-09 · Pain
What this study did
NCT01704339 · Emma Aitken
2012-12 – 2014-03 · End Stage Renal Failure, Neuropathic Pain
What this study did
NCT01713426 · Astellas Pharma Europe Ltd.
Run by former owner Astellas Pharma
2012-07-11 – 2013-09-26 · Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI)
What this study did
NCT01252160 · Astellas Pharma Inc
Run by former owner Astellas Pharma
2010-10-28 – 2013-09-26 · Neuralgia, Postherpetic
What this study did
NCT01416116 · Astellas Pharma Inc
Run by former owner Astellas Pharma
2011-07-06 – 2012-04-25 · or Peripheral Nerve Injury (PNI), Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)
What this study did
Early phase / not applicable (9)
Other / comorbidity
NCT07122973 · Aalborg University
2025-09-17 – 2028-12-31 · Pain, Itch
What this study did
NCT07660510 · Nantes University Hospital
2026-11-20 – 2028-03-01 · Neuropathic Pain, Nociplastic Pain
What this study did
NCT07602387 · Hospital Ambroise Paré Paris
2024-03-12 – 2028-03 · Patients With Taxane-induced Chronic Neuropathic Pain
What this study did
NCT05560516 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2022-12-01 – 2025-12-31 · Qutenza, Duloxetine, Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
What this study did
NCT05726929 · Institut Toulousain d'Ostéopathie
2023-01-11 – 2024-12-08 · Breast Cancer, Neuropathic Pain
What this study did
NCT06197529 · Aalborg University
2023-11-21 – 2024-03-04 · Healthy
What this study did
NCT02441660 · The University of Texas Health Science Center at San Antonio
2016-04 – 2022-05-02 · Spinal Cord Injuries, Neuropathic Pain
What this study did
NCT05158309 · Aalborg University
2021-05-31 – 2021-11-06 · Prolonged Pain, EEG, Resting State Functional Connectivity
What this study did
NCT01200745 · Kyunghee University Medical Center
2010-09 – 2011-02 · Chronic Neck Pain
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT02700815 · Boehringer Ingelheim
2016-05-09 – 2017-07-21 · Acute Pain
What this study did
Phase 2 (1)
Other / comorbidity
NCT06807164 · Centre Oscar Lambret
2025-06-10 – 2026-09-22 · Post-Mastectomy Neuropathic Pain Syndrome
What this study did
Phase 1 (1)
Other / comorbidity
NCT03576508 · Centrexion Therapeutics
2018-06-25 – 2018-09-06 · Knee Osteoarthritis
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02537951 · Erasmus Medical Center
2015-09 – 2016-09 · Small Fiber Neuropathy
What this study did
Appears in other studies (102)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Diabetic Peripheral Neuropathic Pain
NCT05029297 · Arafarma Group, S.A.
2010-11-04 – 2018-10-23 · Diabetic Neuropathy, Painful
What this study did
NCT03113448 · Thammasat University
2017-01-19 – 2018-01-31 · Peripheral Diabetic Neuropathy
What this study did
Other / comorbidity
NCT05093478 · The University of Texas Health Science Center, Houston
2019-09-10 – 2023-11-30 · Non-allergic Rhinitis
What this study did
NCT00471055 · Khon Kaen University
2007-06 – 2007-12 · Osteoarthritis, Knee Joint, Capsicum
What this study did
NCT00003610 · Alliance for Clinical Trials in Oncology
1998-10 – 2006-07 · Head and Neck Cancer, Radiation Toxicity
What this study did
Phase 2/3 (3)
Diabetic Peripheral Neuropathic Pain
NCT01125215 · Mahidol University
2009-09 – 2013-12 · Painful Diabetic Neuropathy
What this study did
NCT00993070 · Thammasat University
2009-10 – 2011-12 · Diabetic Polyneuropathy
What this study did
Other / comorbidity
NCT02823912 · University of Guadalajara
2016-10 – 2017-10 · Dyslipidemia, Overweight or Obesity
What this study did
Phase 2 (16)
Other / comorbidity
NCT07406971 · Instituto Mexicano del Seguro Social
2025-09-01 – 2026-10-31 · Ischemic Stroke
What this study did
NCT04470752 · Georg Kägi, MD
2021-08-24 – 2024-12 · Dysphagia, Late Effect of Stroke
What this study did
NCT04972123 · University of Wisconsin, Madison
2021-07-20 – 2023-08-31 · Syncope, Vasovagal
What this study did
NCT05098067 · Women and Infants Hospital of Rhode Island
2022-05-24 – 2023-03-01 · Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
What this study did
NCT04125563 · Vastra Gotaland Region
2019-06-01 – 2022-08-29 · Cough
What this study did
NCT04918069 · Christian Medical College, Vellore, India
2019-10-18 – 2022-05-14 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT03223350 · Henry Ford Health System
2017-12-20 – 2019-08-05 · Cyclical Vomiting
What this study did
NCT02493257 · The University of Texas Health Science Center, Houston
2014-10 – 2019-08-02 · Nonallergic Irritant Rhinitis
What this study did
NCT03152578 · Panag Pharma Inc.
2017-07-01 – 2019-07-31 · Pain
What this study did
NCT02037464 · Sunnybrook Health Sciences Centre
2014-01 – 2018-01 · Prostate Cancer
What this study did
NCT00693160 · Wake Forest University
2007-12 – 2011-01 · Healthy
What this study did
NCT00795106 · Stamford Hospital
2009-11 – 2010-11 · Myofascial Pain Syndrome
What this study did
NCT00672568 · Anesiva, Inc.
2008-07 – 2008-12 · Rotator Cuff Repair of the Shoulder
What this study did
NCT00683267 · Anesiva, Inc.
2007-09 – 2008-12 · Arthroplasty
What this study did
NCT00088686 · National Institute of Dental and Craniofacial Research (NIDCR)
2004-07 – 2005-10 · Healthy, Tooth Extraction
What this study did
NCT00008476 · National Institute of Dental and Craniofacial Research (NIDCR)
2001-01 – 2004-01 · Facial Pain
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT03122145 · University of Florida
2017-05-23 – 2019-02-28 · Healthy
What this study did
NCT02183519 · University of Florida
2014-10 – 2015-08 · Cough, Parkinson's Disease
What this study did
NCT01854268 · University of Florida
2013-05 – 2014-05 · Cough
What this study did
NCT00004316 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1995-06 – 2007-08 · Interstitial Cystitis, Vulvar Diseases
What this study did
Phase 1 (21)
Diabetic Peripheral Neuropathic Pain
NCT07260656 · Carilion Clinic
2025-11-26 – 2027-11 · Diabetic Neuropathies, Painful, Diabetic Foot, Diabetic Peripheral Neuropathy
What this study did
Other / comorbidity
NCT06971250 · Stefan Heber
2025-05-08 – 2025-05-28 · Pain
What this study did
NCT04398719 · Yale University
2021-05-07 – 2024-12-11 · CBD, Healthy
What this study did
NCT05649228 · Carilion Clinic
2022-12-13 – 2024-01-11 · Pain Management
What this study did
NCT06809569 · Merck Sharp & Dohme LLC
2023-09-25 – 2023-12-15 · Healthy
What this study did
NCT05226299 · University of Montana
2021-05-01 – 2022-08-30 · Cough
What this study did
NCT04256733 · University of Montana
2019-05-01 – 2021-02-13 · Cough
What this study did
NCT03944889 · Toronto Rehabilitation Institute
2019-07-01 – 2020-12-01 · Central Sensitisation
What this study did
NCT02390089 · University of Florida
2015-04 – 2019-02-13 · Parkinson's Disease
What this study did
NCT02710110 · University of Florida
2016-04 – 2019-02-07 · Amyotrophic Lateral Sclerosis
What this study did
NCT03472677 · Centrexion Therapeutics
2018-03-21 – 2018-08-03 · Osteoarthritis, Knee
What this study did
NCT02710162 · University of Florida
2016-04 – 2017-12-19 · Amyotrophic Lateral Sclerosis
What this study did
NCT01541436 · Wake Forest University Health Sciences
2012-03 – 2017-04-30 · Pain
What this study did
NCT02766517 · Eli Lilly and Company
2016-09-28 – 2017-01-01 · Migraine Disorders
What this study did
NCT02240329 · University of Florida
2013-03 – 2015-06 · TBI, Brain Injury
What this study did
NCT01797796 · Pfizer
2013-04 – 2013-07 · Healthy
What this study did
NCT01883102 · Mayo Clinic
2013-06 – 2013-06 · Pain
What this study did
NCT01595620 · Yale University
2011-11-09 – 2012-04-19 · Pain
What this study did
NCT02695745 · Purdue Pharma LP
2011-09 – 2012-01 · Pain
What this study did
NCT01147432 · Pfizer
2010-08 – 2011-10 · Healthy
What this study did
Phase 4 (12)
Other / comorbidity
NCT06040190 · Federal University of Minas Gerais
2023-11-01 – 2026-07-01 · Burning Mouth Syndrome
What this study did
NCT05298202 · University of Nebraska
2022-05-25 – 2022-10-01 · Acute Exercise, Heat Exposure
What this study did
NCT04283292 · University of Virginia
2020-12-01 – 2022-03-18 · Cannabinoid Hyperemesis Syndrome
What this study did
NCT04361149 · Toronto Rehabilitation Institute
2019-10-01 – 2020-03-10 · Central Sensitisation, Motor Disorders
What this study did
NCT03124407 · Propella Therapeutics
2016-07 – 2016-10 · Osteoarthritis, Knee
What this study did
NCT01862523 · Universitaire Ziekenhuizen KU Leuven
2012-02 – 2014-12 · Rhinitis
What this study did
NCT01974037 · Zhiming Zhu
2013-05 – 2013-12 · Volunteers
What this study did
NCT01223820 · Universitaire Ziekenhuizen KU Leuven
2011-01 – 2011-09 · Idiopathic Rhinitis Patients, Healthy Controls
What this study did
NCT00771511 · Columbia University
2010-10 – 2011-06 · Labor Pain, Pregnancy Loss, Labor Induction
What this study did
NCT00655811 · Wake Forest University
2008-02 – 2009-10 · Healthy
What this study did
NCT00697034 · Wake Forest University
2006-06 – 2008-12 · Psoriasis
What this study did
NCT00176969 · University of Minnesota
1997-08 – 2000-06 · Alopecia Areata
What this study did
Early phase / not applicable (41)
Other / comorbidity
NCT07443553 · Northwestern University
2026-10-31 – 2029-12-31 · Postamputation Pain
What this study did
NCT07755930 · Aalborg University
2026-08-01 – 2027-12-31 · Marsili Syndrome
What this study did
NCT04415892 · Universitaire Ziekenhuizen KU Leuven
2019-10-01 – 2026-12-01 · Chemotherapy-induced Peripheral Neuropathy
What this study did
NCT07054840 · University of Delaware
2025-08-26 – 2026-05-31 · Aging, Older Adults, Pain, Motor Learning
What this study did
NCT07598994 · Istanbul University
2025-08-28 – 2026-04-06 · Temporomandibular Disorders (TMD), Temporomandibular Pain
What this study did
NCT05958173 · Hospital de Mataró
2023-09-01 – 2025-12-31 · Oropharyngeal Dysphagia, Swallowing Disorder
What this study did
NCT05720871 · Hospital de Mataró
2022-11-28 – 2025-09 · Oropharyngeal Dysphagia, Stroke, Stroke, Complication, Swallowing Disorder
What this study did
NCT07625475 · University of Guelph
2024-05-01 – 2025-04-30 · Hyperalgesia, Pain Perception, Central Nervous System Sensitization, Pain Threshold
What this study did
NCT05713019 · Imperial College London
2023-02-28 – 2024-08-31 · Cough
What this study did
NCT05059418 · Malmö University
2021-11-01 – 2024-06-30 · Burning Mouth Syndrome
What this study did
NCT05625776 · University of Delaware
2023-03-22 – 2023-11-16 · Pain, Acute, Cognition
What this study did
NCT05835258 · Fundació Eurecat
2023-05-30 – 2023-07-14 · Bioavailability
What this study did
NCT03722849 · Stuart Mazzone
2019-03-01 – 2022-05-13 · Cough
What this study did
NCT04741620 · Hospital de Mataró
2019-01-17 – 2022-03-27 · Oropharyngeal Dysphagia, Dysphagia, Swallowing Disorder
What this study did
NCT04700007 · Aalborg University
2021-01-18 – 2021-12-31 · Itch
What this study did
NCT03883880 · Purdue University
2019-01-05 – 2021-12-01 · Diet, Food Choice, Taste
What this study did
NCT04485689 · Aalborg University
2020-07-01 – 2020-12 · Healthy
What this study did
NCT03330639 · University of Nebraska
2020-06-23 – 2020-06-23 · Headache Disorders
What this study did
NCT03587220 · Aalborg University
2018-08-01 – 2019-12-31 · Capsaicin, Ultaviolet B Light Burn, Neuropathic Pain, Lidocaine
What this study did
NCT03859583 · George Mason University
2018-05-29 – 2019-08 · Obesity, Insulin Resistance
What this study did
NCT02551029 · Maastricht University Medical Center
2016-02 – 2019-07-26 · Irritable Bowel Syndrome, Colonic Diseases, Functional, Dyspepsia, Gastrointestinal Diseases, Abdominal Pain, Visceral Pain
What this study did
NCT03102710 · Massachusetts General Hospital
2016-05 – 2019-03 · Pain
What this study did
NCT04052178 · Hospital de Mataró
2016-02-10 – 2018-12-21 · Swallowing Disorder, Dysphagia, Stroke, Neurophysiologic Abnormality
What this study did
NCT03146689 · University of Nottingham
2017-08-04 – 2018-10-16 · Osteoarthritis, Knee
What this study did
NCT03216707 · Assiut University
2017-09-01 – 2018-06-15 · Pain
What this study did
NCT03281941 · National Health Service, United Kingdom
2016-08-06 – 2018-02-01 · Asthma Chronic, Cough
What this study did
NCT03132142 · Aalborg University
2017-04 – 2017-08 · Pain, Pruritus, Neuropathic Pain, Dermatology/Skin - Other
What this study did
NCT02603783 · Maastricht University Medical Center
2015-11 – 2017-02 · TRPV1 Protein, Human, Capsaicin, Electric Impedance, Esophagus, Intracellular Space, Pain Measurement, Microscopy, Electron
What this study did
NCT02334605 · Universitaire Ziekenhuizen KU Leuven
2015-01 – 2016-12 · Nasal Hyper Reactivity
What this study did
NCT02377180 · Insel Gruppe AG, University Hospital Bern
2014-09 – 2016-12 · Healthy
What this study did
NCT01777087 · University of Pittsburgh
2013-01 – 2016-03 · Pain
What this study did
NCT02138630 · University of Prince Edward Island
2014-06 – 2016-01 · Metabolism, Exercise
What this study did
NCT02346903 · Bassett Healthcare
2013-04 – 2015-08 · Chest Pain
What this study did
NCT02346916 · Bassett Healthcare
2013-10 – 2015-08 · Chest Pain
What this study did
NCT01807832 · Tel-Aviv Sourasky Medical Center
2013-03 – 2013-12 · Chronic Cough
What this study did
NCT02882555 · Central Hospital, Nancy, France
2012-06 – 2013-12 · Cough
What this study did
NCT00693407 · National University Hospital, Singapore
2008-09 – 2012-09 · Functional Dyspepsia
What this study did
NCT01667523 · Maastricht University Medical Center
2011-02 – 2011-12 · Healthy
What this study did
NCT01540877 · Ruhr University of Bochum
2011-04 – 2011-09 · Ipsi- and Contralateral Hypoesthesia
What this study did
NCT00875537 · University of Copenhagen
2009-01 – 2010-06 · Burning Mouth Syndrome
What this study did

Competitive landscape

This drug's own stage for Diabetic Peripheral Neuropathic Pain: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Capsaicin (Qutenza): this drugApprovedSmall moleculeTRPV1 (transient receptor potential vanilloid 1) channelReliable signal
NCT01533428: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 (Baseline to between Weeks 2 to 8): Capsaicin 8% -27.44% (Standard Deviation 26.79) vs Placebo -20.85% (Standard Deviation 28.92)
NCT01478607: Norfolk QOL-DN total score change from baseline to end of study: 30 min capsaicin + SOC -27.6% (mean difference vs SOC alone -20.9, 90% CI -31.7 to -10.1); 60 min capsaicin + SOC -32.8% (mean difference vs SOC alone -26.1, 90% CI -36.8 to -15.4); SOC alone -6.7%.
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)Partial signal
NCT01179672: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score (Baseline, 12 weeks): Duloxetine -2.4 units on a scale (Standard Error 0.14) vs Placebo -1.97 units on a scale (Standard Error 0.14)
NCT00408993: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score (Baseline and 12 weeks): Duloxetine -2.69 units on a scale (Standard Error 0.19) vs Placebo -2.31 units on a scale (Standard Error 0.18) missed
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signalNo reviewed efficacy summary in this indication
TapentadolApprovedSmall moleculeMu-opioid receptor and norepinephrine transporter (NET)Reliable signal
NCT01041859: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12 (Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)): DB Tapentadol ER 0.28 units on a scale (Standard Deviation 2.04) vs DB Placebo 1.3 units on a scale (Standard Deviation 2.43)
NCT00455520: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12 (Baseline and 12 weeks): Tapentadol ER -0.1 scores on a scale (Standard Deviation 1.69) vs Placebo 1.3 scores on a scale (Standard Deviation 2.41)
CrisugabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsReliable signal
NCT04647773: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001)
MirogabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsPartial signal
NCT04094662: Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301
NCT02318706: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain (Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])): DS-5565 15mg QD — Week 1: -0.39 units on a scale (Standard Deviation 0.67); Week 2: -0.6 units on a scale (Standard Deviation 0.9); Week 3: -0.78 units on a scale (Standard Deviation 1.02); Week 4: -0.87 units on a scale (Standard Deviation 1.13); Week 5: -0.97 units on a scale (Standard Deviation 1.2); Week 6: -1.01 units on a scale (Standard Deviation 1.32); Week 7: -1.06 units on a scale (Standard Deviation 1.4); Week 8: -1.07 units on a scale (Standard Deviation 1.49); Week 9: -1.13 units on a scale (Standard Deviation 1.49); Week 10: -1.19 units on a scale (Standard Deviation 1.56); Week 11: -1.23 units on a scale (Standard Deviation 1.57); Week 12: -1.24 units on a scale (Standard Deviation 1.6); Week 13: -1.27 units on a scale (Standard Deviation 1.63); Week 14: -1.34 units on a scale (Standard Deviation 1.74) | DS-5565 20 mg (10 mg BID) — Week 1: -0.4 units on a scale (Standard Deviation 0.85); Week 2: -0.72 units on a scale (Standard Deviation 1.12); Week 3: -0.84 units on a scale (Standard Deviation 1.22); Week 4: -0.94 units on a scale (Standard Deviation 1.38); Week 5: -1.06 units on a scale (Standard Deviation 1.5); Week 6: -1.13 units on a scale (Standard Deviation 1.52); Week 7: -1.13 units on a scale (Standard Deviation 1.59); Week 8: -1.26 units on a scale (Standard Deviation 1.59); Week 9: -1.27 units on a scale (Standard Deviation 1.56); Week 10: -1.33 units on a scale (Standard Deviation 1.65); Week 11: -1.36 units on a scale (Standard Deviation 1.64); Week 12: -1.36 units on a scale (Standard Deviation 1.67); Week 13: -1.43 units on a scale (Standard Deviation 1.72); Week 14: -1.47 units on a scale (Standard Deviation 1.69) | DS-5565 30 mg (15 mg BID) — Week 1: -0.6 units on a scale (Standard Deviation 1.01); Week 2: -1 units on a scale (Standard Deviation 1.27); Week 3: -1.33 units on a scale (Standard Deviation 1.49); Week 4: -1.43 units on a scale (Standard Deviation 1.63); Week 5: -1.48 units on a scale (Standard Deviation 1.68); Week 6: -1.58 units on a scale (Standard Deviation 1.73); Week 7: -1.57 units on a scale (Standard Deviation 1.72); Week 8: -1.53 units on a scale (Standard Deviation 1.79); Week 9: -1.63 units on a scale (Standard Deviation 1.76); Week 10: -1.67 units on a scale (Standard Deviation 1.83); Week 11: -1.69 units on a scale (Standard Deviation 1.8); Week 12: -1.82 units on a scale (Standard Deviation 1.84); Week 13: -1.85 units on a scale (Standard Deviation 1.93); Week 14: -1.88 units on a scale (Standard Deviation 1.88) vs Placebo — Week 1: -0.26 units on a scale (Standard Deviation 0.79); Week 2: -0.46 units on a scale (Standard Deviation 0.96); Week 3: -0.57 units on a scale (Standard Deviation 1.08); Week 4: -0.7 units on a scale (Standard Deviation 1.12); Week 5: -0.84 units on a scale (Standard Deviation 1.17); Week 6: -0.92 units on a scale (Standard Deviation 1.25); Week 7: -1.03 units on a scale (Standard Deviation 1.31); Week 8: -1.09 units on a scale (Standard Deviation 1.39); Week 9: -1.16 units on a scale (Standard Deviation 1.42); Week 10: -1.18 units on a scale (Standard Deviation 1.44); Week 11: -1.25 units on a scale (Standard Deviation 1.46); Week 12: -1.28 units on a scale (Standard Deviation 1.5); Week 13: -1.32 units on a scale (Standard Deviation 1.55); Week 14: -1.37 units on a scale (Standard Deviation 1.6)
Suzetrigine (Journavx)Phase 3Small moleculeVoltage-gated sodium channel NaV1.8Partial signal
NCT05660538: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70)
HL-1186Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JMKX000623Phase 2Small moleculeVoltage-gated sodium channel NaV1.8Partial signalNo reviewed efficacy summary in this indication
LY4065967Phase 2Small moleculeAngiotensin II type 2 receptor (AT2R) (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Nispomeben (NRD135S.E1)Phase 2Small molecule—Partial signal
NCT05480228: Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted missed
NCT02345291: Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). missed
PilavapadinPhase 2Small moleculeAP2-associated kinase 1 (AAK1)Partial signal
NCT06203002: Change from baseline to Week 8 in ADPS: -1.74 (10 mg), -1.70 (20 mg/10 mg titration), -1.38 (20 mg), vs -1.31 (placebo); overall primary endpoint p=0.11 (not significant, as the statistical plan required all arms to separate from placebo) missed
NCT04455633: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale (Baseline (Week 2 of the Run-in period) to Week 6): LX9211 100 mg/10 mg -1.39 score on a scale (95% CI -1.77 to -1.01) | LX9211 200 mg/20 mg -1.27 score on a scale (95% CI -1.66 to -0.88) vs Placebo -0.72 score on a scale (95% CI -1.08 to -0.36)
Pirenzepine (topical)Phase 2Small moleculeMuscarinic M1 receptor (antagonist)Partial signalFeatured results are safety only in this race
VX-993Phase 2Small moleculeVoltage-gated sodium channel NaV1.8not yet gradedNo reviewed efficacy summary in this indication
AJH-2947
Phase 1(overall)
Small molecule—Partial signalNo reviewed efficacy summary in this indication
HRS-2129Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
QR-333DiscontinuedBotanical—not yet gradedNo reviewed efficacy summary in this indication
TanezumabDiscontinuedMonoclonal antibodyNerve growth factor (NGF)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Capsaicin (Qutenza) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicablePain, ItchRecruiting
Est. primary completion 2026-12-31 · NCT07122973 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Early phase / not applicablePatients With Taxane-induced Chronic Neuropathic PainRecruiting
Est. primary completion 2027-03 · NCT07602387 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Coccyx Disorder, Neuropathic Pain, CoccygodyniaRecruiting
Est. primary completion 2027-05-08 · NCT06023706 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Peripheral Neuropathy Due to ChemotherapyRecruiting
Est. primary completion 2027-11-30 · NCT06744816 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 4Osteoarthritis Hand, Neuropathic PainRecruiting
Est. primary completion 2028-01-01 · NCT06444919 · CT.gov ↗
What to watch
March 2028 (2)
Phase 3Chemotherapy-induced Peripheral NeuropathyRecruiting
Est. primary completion 2028-03 · NCT05840562 · CT.gov ↗
What to watch
Early phase / not applicableNeuropathic Pain, Nociplastic PainNot yet recruiting
Est. primary completion 2028-03-01 · NCT07660510 · CT.gov ↗
What to watch
July 2028 (1)
Phase 3Neuropathic Pain, Chronic PainRecruiting
Est. primary completion 2028-07-05 · NCT05997979 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026PresentationPhase III RISE results at IASP 2026: one of the primary endpoints met (average pain intensity, weeks 2-12)